Hostname: page-component-76fb5796d-wq484 Total loading time: 0 Render date: 2024-04-27T13:14:25.995Z Has data issue: false hasContentIssue false
  • English
  • Français

Congenital malformations caused by psychotropic drugs in pregnancy

Published online by Cambridge University Press:  18 September 2015

G. de Cuypere ,
Ph. Rombaut  and
M. van Moffaert
Get access Rights & Permissions [Opens in a new window]

Summary

After a description of the harmful effects of psychotropic drugs as well as of the moments of vulnerability to any teratogenic effect, this paper reviews prospective, retrospective and epidemiological studies of the teratogenic effects of anticonvulsants (phenytoin, valproic acid, carbamazepine and barbiturates), lithium, anti-psychotics, benzodiazepines and anti-depressive agents. It is found that the results of these studies are not unequivocal. Only lithium and valproic acid are shown to be teratogenic. In cases where malformations of the fetus are observed, the treatment often consisted in a combination of various psychotropic drugs.

The review is completed with data on the psychopharmacological problems during delivery and their side-effects on the newborn.

Keywords

anticonvulsantslithiumantipsychotic drugsbenzodiazepinesantidepressantsteratogenicitypregnancyanti-epilepticalithiumantipsychoticabenzodiazepinen en antidepressivateratogeniciteitzwangerschap
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 4 , Issue 4 , December 1992 , pp. 77 - 85
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

3.Billeaud, Cl, Martin, Cl.Effets nocifs des drogues sur le développement du foetus et son adaptation néo-natale. Méd inf 1985; 92: 145–58.Google Scholar
4.Hill, LM, Kleinberg, F.Effects of drugs and chemicals on the fetus and newborn. Mayo Clin Proc, Part 1, 1984; 59: 707–16; Part 2, 1984; 59: 755–65.CrossRefGoogle ScholarPubMed
6.Dalessio, DM.Seizure disorders and pregnancy. New Engl J Med 1985; 312: 559.CrossRefGoogle ScholarPubMed
8.Hanson, JW, Smith, DW.The fetal hydantoin syndrome. J Pediatr 1975; 87: 285–90.CrossRefGoogle ScholarPubMed
10.Meinardi, H.Het verband tussen het gebruik van anti-epileptica door de zwangere vrouw en het ontstaan van aangeboren afwijkingen bij haar kind. Ned Tijdsch Geneesk 1983; 127: 2012–6.Google Scholar
16.Lindhout, D, Meinardi, H.Gebruik van valpro'inezuur gedurende de zwangerschap: een indicatie voor prenataal onderzoek op spina bifida. Ned Tijdsch Geneesk 1984; 128: 52.Google ScholarPubMed
17.Yerby, M.Problems and management of the pregnant woman with epilepsy. Epilepsia 1987; 28 (suppl.3): S29–S36.CrossRefGoogle ScholarPubMed
18.Lindhout, D, Meinardi, H, Barth, PG.Hazards of fetal exposure in drug combinations. In : Janz, D, Bossi, L, Dam, M, Helge, H, Rickens, A, Schmidt, D, red. Epilepsy, Pregnancy and the Child. New York: Raven Press, 1982: 275–81.Google Scholar
20.Nelson, MM, Forpar, J.Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. Br med J 1971; 1: 523–7.CrossRefGoogle ScholarPubMed
22.Weinstein, MR.Lithium treatment of women during pregnancy and in the postdelivery period. In : Johnson, FN, red. Handbook of lithium therapy. Lancaster (England): MTP Press, 1980: 421–9.CrossRefGoogle Scholar
25.Haaften, M van, Bruinse, HW.Lithium en zwangerschap: aanbevo-len richtlijnen. Ned Tijdschr Geneeskd 1984; 128: 2103–5.Google Scholar
26.Schou, M.Lithium treatment during pregnancy, delivery and lactation: an update. J clin Psychiat 1990; 51: 410–3.Google ScholarPubMed
28.Slone, D, Siskind, V, Heinone, O, Manson, R, Kaufman, D, Shapiro, S.Antenatal exposute to the phenothiazines in relation to congenital malformations, perinatal mortality rate birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977; 128: 486–8.CrossRefGoogle Scholar
29.Rumeau-Rouquette, C, Goujard, J, Huel, G.Possible teratogenic effects of phenothiazines in human beings. Teratol 1976; 15: 57–64.CrossRefGoogle Scholar
31.Sobel, DE.Fetal damage due to ECT, insulin coma, chlorpromazine or reserpine. Arch gen Psychiat 1960; 5: 606–11.CrossRefGoogle Scholar
35.Edlund, MJ, Craig, TJ.Antipsychotic drug use and birth defects: an epidemiologic reassessment. Compr Psychiat 1984; 25: 32–7.CrossRefGoogle ScholarPubMed
40.Hanson, JW, Oakley, GP.Haloperidol and limb deformity. JAMA 1975; 231: 26.CrossRefGoogle ScholarPubMed
42.Elia, J, Katz, I, Simpson, GM.Teratogenicity of psychotherapeutic medications. Psychopharmacol Bull 1987; 23: 531–86.Google ScholarPubMed
45.Aarskog, D.Association between maternal intake of diazepam and oral clefts. Lancet 1975; 2:921.CrossRefGoogle ScholarPubMed
46.Rosenberg, L, Mitchell, A, Parsells, J, Pashayan, HS, Louik, C, Shapiro, S.Lack of relation of oral cleft to diazepam use during pregnancy. N Engl J Med 1983; 309: 1282–5.CrossRefGoogle ScholarPubMed
47.Milkovich, L, Van Den Berg, BJ.Effects of prenatal meprobamate and chlordiazepoxide hydrochloride on human embryonic and fetal development. N Engl J Med 1983; 291: 1268–71.CrossRefGoogle Scholar
52.Drug, F.D.A.Bulletin: Teratogenicity of minor tranquillizers, 1975; 5: 14–5.Google Scholar
54.Morrow, AW.Limb deformities associated with iminodibenzyl hydrochloride. Med J Austr 1972; 59: 658–9.Google Scholar
55.Australian Drug Evaluation Committee. Tricyclic antidepressants and limb reduction deformitites. Med J Austr 1973; 1: 768–9.CrossRefGoogle Scholar
62.Bracken, MB, Holford, TR.Exposure to prescribed drugs in pregnancy and association with congenital malformations. Obstet Gynecol 1981; 58: 336–44.Google ScholarPubMed